A Registry for People With T-cell Lymphoma
a study on Lymphoma T Cell Lymphoma Leukemia Lymphoproliferative Disorders Epstein Barr Virus Mycosis Fungoides Sezary Disease Cutaneous T-Cell Lymphoma ALK Positive Non-Hodgkin Lymphoma
Summary
- Location
- at San Diego, California and other locations
- Dates
- study startedcompletion around
Description
Summary
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Official Title
The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
Keywords
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma, 23-190, Memorial Sloan Kettering Cancer Center, T-cell Lymphoma Master Repository, TCLMR, Mycoses, Epstein-Barr Virus Infections, Lymphoma, Leukemia, Non-Hodgkin Lymphoma, Lymphoma, T-Cell, Peripheral, T-Cell Leukemia, Adult T-Cell Leukemia-Lymphoma, Lymphoma, Large-Cell, Anaplastic, Lymphoma, T-Cell, Cutaneous, Extranodal NK-T-Cell Lymphoma, Prolymphocytic Leukemia, Large Granular Lymphocytic Leukemia, Leukemia, Prolymphocytic, T-Cell, Lymphoproliferative Disorders, Immunoblastic Lymphadenopathy, Panniculitis, Hydroa Vacciniforme, Aggression
Eligibility
You can join if…
- Written informed consent
- Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
- Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Aggressive NK-cell leukemia
- Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
- Chronic active EBV infection of T- and NK-cell type, systemic form
- Hydroa vacciniforme-like lymphoproliferative disorder
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Intestinal T-cell lymphoma, not otherwise specified (NOS)
- Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
- Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
- Primary cutaneous Gamma-Delta T-cell lymphoma
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
- Peripheral T-cell lymphoma, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Follicular T-cell lymphoma
- Nodal peripheral T-cell lymphoma with TFH phenotype
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Breast-implant associated anaplastic large cell lymphoma.
- NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
You CAN'T join if...
- Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
- Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Locations
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)
not yet accepting patients
San Diego California 92103 United States - City of Hope Cancer Center (Data collection only)
not yet accepting patients
Duarte California 91010 United States - Memorial Sloan Kettering at Basking Ridge (All protocol activities)
accepting new patients
Basking Ridge New Jersey 07920 United States - Memorial Sloan Kettering Monmouth (All protocol activities)
accepting new patients
Middletown New Jersey 07748 United States
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Links
- Memorial Sloan Kettering Cancer Center
- ID
- NCT05978141
- Study Type
- Observational [Patient Registry]
- Participants
- Expecting 1000 study participants
- Last Updated